Jounce Therapeutics Completed Enrollment in First Cohort of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
35
Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014

CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that the company completed enrollment in the first cohort for its Phase 1 dose escalation clinical trial of JTX-4014 as monotherapy in patients with solid tumors. JTX-4014 is a fully human IgG4 monoclonal antibody designed to specifically bind to PD-1 and block its interaction with its ligands, PD-L1 and PD-L2, to augment anti-tumor T cell activity. Jounce is developing JTX-4014 for potential use in combination with its pipeline of future product candidates.

“We believe combination therapy will be the mainstay of cancer immunotherapy treatment and that PD-1 checkpoint inhibitors like JTX-4014 will be an important component of future regimens,” said Elizabeth Trehu, M.D., chief medical officer of Jounce Therapeutics. “As we continue to build and progress our immunotherapy pipeline, including macrophage and other cold tumor target treatments, we believe it is important for us to have our own PD-1 inhibitor to potentially combine with these novel agents.”

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics and to identify the recommended Phase 2 dose of JTX-4014 monotherapy in patients with advanced solid tumors. For more information on this trial, please visit https://clinicaltrials.gov (Identifier: NCT03790488).

About JTX-4014 JTX-4014 is a well-characterized fully human IgG4 monoclonal antibody designed to block binding to PD-L1 and PD-L2. Jounce is developing JTX-4014 for potential use in combination with its pipeline of future product candidates. JTX-4014 is currently in Phase 1 clinical development.

About Jounce Therapeutics Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment (TME) to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce has three development stage programs: its two clinical product candidates, JTX-2011, a monoclonal antibody that binds to and activates ICOS, and JTX-4014, a monoclonal antibody that binds to PD-1 to be used in combination with its pipeline of future product candidates, and JTX-8064, a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2 (LILRB2) that is currently in the IND-enabling phase. For more information, please visit www.jouncetx.com.

Investor Contact: Komal Joshi Jounce Therapeutics, Inc. (857) 320-2523 kjoshi@jouncetx.com

Media Contact: Gina Nugent The Yates Network (617) 460-3579 gina@theyatesnetwork.com

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 6

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Perkins Rolls Out Mahjong to Revive Family Bonds

Updated Category News Views 4

Perkins Ditches the Phones, Sparks True Connection No doubt about it, folks—Perkins Restaurant & Bakery has cooked up something special to bring families back to the table. Not just for pancakes or pies this time, but for a little classic game action with their limited-edition Mahjong set. Love it or leave it, this is Perkins tapping into the magic of togetherness...

Continue Reading
AHN Healthcare@Home Celebrates Fourth Top Workplace Win

Updated Category News Views 4

Four-Time Top Workplace Champ You want to talk consistency? Let's talk about AHN Healthcare@Home pulling in that Pittsburgh Top Workplace award four years running. It's no small feat, especially in the healthcare sector where employee burnout isn't just a buzzword—it's a daily challenge. How did a home health and hospice outfit like AHN land this honor? Well, it's all...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 5

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
RiskScout Rides High on Funding, Tackles Financial Crime

Updated Category News Views 4

A Fresh Injection to Combat Financial Crime Capital's flowing into RiskScout's coffers thanks to a new funding round, and it's not just about cash—it’s about gearing up for a battle against financial crime. The round was led by LiveOak Ventures, who aren't new to the block, alongside other players like Castle Creek Launchpad and Alloy Labs. After tripling their...

Continue Reading
Schneider Electric Pushes Water Management Tech at WEFTEC

Updated Category News Views 6

Looks like Schneider Electric is diving headfirst into the choppy waters of utility management with its latest tech showcase at WEFTEC 2026. And trust me, the timing couldn't be more spot-on. With North America's water and wastewater systems groaning under the weight of aging infrastructure and cybersecurity threats, it’s about time someone brought something fresh to...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 4

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
J.P. Morgan, Thunes Partner for Global Payment Integration

Updated Category News Views 4

You don't need a crystal ball to see J.P. Morgan's playing the long game by teaming up with Thunes. In this world, where cash is digital and the reach is global, it's all about speed and scale—brushing elbows with the right partners makes all the difference. Sometimes it's about knowing when to hitch your wagon to a reliable workhorse, especially when global commerce is...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 4

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Nailah Thorbourne's Vlair Shapewear: Fashion Freedom

Updated Category News Views 3

Fashion with a Punch: Nailah Thorbourne's New Venture You'd think from the way the fashion industry's been humming along that someone would've cracked the code on shapewear a long time ago, right? But alas, it takes Nailah Thorbourne to step out of Brick & Lace's spotlight and into this shapely market with Vlair Shapewear. Apparently, what most overlooked in comfort, she...

Continue Reading

Top 5 Most Recently Viewed Articles

ECB Sees Stable Euro Zone Inflation Amid Rate Cut Speculation

Updated Category News Views 34

ECB Insights on Euro Zone Inflation Stability MADRID - In a recent interview, José Luis Escriva, a member of the European Central Bank (ECB) board and the governor of the Bank of Spain, expressed confidence that current inflation projections for the euro zone remain stable. He noted that there are no significant indicators suggesting inflation is likely to deviate from...

Continue Reading
San Francisco's Nonprofits Struggle Amid Bureaucratic Challenges

Updated Category News Views 121

Nonprofits in San Francisco Face Bureaucratic Challenges The recent findings from the San Francisco Civil Grand Jury shed light on numerous obstacles facing social services nonprofits in the city. Despite significant financial investment exceeding a billion dollars annually for social services, many of these programs face hurdles that hinder effective service delivery....

Continue Reading
BTM Industrial Welcomes David Hietikko as New VP for Metalworking

Updated Category News Views 54

BTM Industrial kicked off a bold new chapter back in 2024 with the appointment of David Hietikko as Vice President of its fresh Metalworking Division. Desks were buzzing over this strategic shift aimed at optimizing how the company handles asset disposition in the metalworking game. With Hietikko on board, they were looking to step up their game, aiming for maximum value...

Continue Reading
Opus IVS™ Sets New Standards with Eight Patent Innovations

Updated Category News Views 226

Opus IVS™ Expands Its Patent Portfolio Driving innovation in the automotive servicing industry Opus IVS™, a leading name in automotive diagnostics, programming, and remote support, has taken a significant step forward by securing eight new U.S. patents recently. This accomplishment underscores the company's dedication to enhancing vehicle service intelligence and...

Continue Reading
EVS Broadcast Equipment Enhances Share Buyback Program

Updated Category News Views 123

EVS Broadcast Equipment Updates on Share Buyback Program EVS Broadcast Equipment is excited to share the latest updates regarding its ongoing share buyback program, which was originally announced in late November. This strategic initiative is designed to enhance shareholder value and demonstrate the company’s commitment to maintaining a robust capital structure in a...

Continue Reading